AS AN INVESTOR I WONDER HOW LONG IT IS BEFORE A R/S IS REQUIRED?
The first 180 day period ends Sept.10,2017. The second 180 day period ends March 18,2018. If additional time is required they may be granted an additional 45 days(see PPHM as an example). This would take the company up until early May 2018. So IF a R/S is required it COULD COME as late as 10 MONTHS from today.
WHAT IS NEEDED TO BRING THE SHARE PRICE OVER $1 FOR TEN DAYS?
In my opinion good news is needed to raise the share price. The bears and shorters take advantage of the absence of news. What news might we expect or hope for over the next 10 months?
1. In September 2017(2 months from now) we may receive top-line data from the phase 2 fourth line NSCLC trial using HS-110 plus low dose cyclophosphamide. Low dose CP has been used in combination with several CAR-T drugs- so its synergy with HS-110 will be of great interest.
2. Top-line data from the phase 2 HS-110 plus Opdivo NSCLC trial should be available in March 2018. However as this trial is open-label we may receive interim data at any time. It could come next week, or along with HS-110 plus CP data in September.
3. There could be further milestones hit in the Pelican trials triggering more of the $15 million grant. Recent Pelican news moved the share price up 25%.
4. There could be news from the Zika trial which would trigger some of its $1 million funding grant.
5. There could be partnering news. Clearly all six checkpoint inhibitor drug manufacturers will be following the HS-110 plus Opdivo trial. This is an open-label trial and both HTBX management, and big pharmas under confidentiality agreements, are watching the maturing data. CEO Wolf mentioned Merck, BMY and AZN as being interested. IF HS-110 can double or triple the effectiveness of their checkpoint inhibitors - they will be very interested!
6. And there could be more news from Pelican or Shattuck Labs or even an overall buy-out of Heat, Pelican and Shattuck Labs. Retail investors are always the last to know.
In my opinion the science and the off-the-shelf business model are great. At the present time the bears and shorters are playing their games. I remain long...I buy on dips...and am going on an extended holiday! Good luck to all longs!
"The refusal of the real is the number one dogma of our time" Rene Girard
